Syndax Pharmaceuticals
- Country
- 🇺🇸United States
- Ownership
- -
- Employees
- 184
- Market Cap
- $1.7B
- Introduction
Syndax Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company engaged in the development of cancer therapies. Its product candidates include SNDX-5613 and SNDX-6352. The company was founded by Richard A. Heyman, Eckard Weber, Peter Ordentlich, Ronald M. Evans and Michael Downes on October 11, 2005 and is headquartered in Waltham, MA.
Ph1b/2 Dose-Escalation Study of Entinostat With Pembrolizumab in NSCLC With Expansion Cohorts in NSCLC, Melanoma, and Colorectal Cancer
- Conditions
- Non-Small Cell Lung CancerMelanomaMismatch Repair-Proficient Colorectal Cancer
- Interventions
- First Posted Date
- 2015-05-07
- Last Posted Date
- 2023-09-21
- Lead Sponsor
- Syndax Pharmaceuticals
- Target Recruit Count
- 196
- Registration Number
- NCT02437136
- Locations
- 🇺🇸
Dana Farber Cancer Institution, Boston, Massachusetts, United States
🇺🇸The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States
🇺🇸Memorial Sloan Kettering Cancer Center, New York, New York, United States
Phase 2 Study of Fulvestrant With and Without Entinostat in Postmenopausal Women With ER+ Advanced Breast Cancer
- First Posted Date
- 2014-04-16
- Last Posted Date
- 2014-10-08
- Lead Sponsor
- Syndax Pharmaceuticals
- Registration Number
- NCT02115594
- Locations
- 🇺🇸
Tennessee Oncololgy, Nashville, Tennessee, United States
Study to Assess Food Effect on Pharmacokinetics of Entinostat in Subjects With Breast Cancer or Non-Small Cell Lung Cancer
- Conditions
- Lung CancerNon Small Cell Lung Cancer (NSCLC)Estrogen Receptor Breast CancerBreast Cancer
- Interventions
- First Posted Date
- 2012-05-09
- Last Posted Date
- 2021-11-19
- Lead Sponsor
- Syndax Pharmaceuticals
- Target Recruit Count
- 14
- Registration Number
- NCT01594398
- Locations
- 🇺🇸
Sarah Cannon Research Institute, Nashville, Tennessee, United States
🇺🇸Florida Cancer Specialists, Sarasota, Florida, United States
🇺🇸Peggy and Charles Stephenson Cancer Center, Oklahoma City, Oklahoma, United States
A Phase 2 Multi-Center Study of Entinostat (SNDX-275) in Patient With Relapsed or Refractory Hodgkin's Lymphoma
- First Posted Date
- 2009-03-20
- Last Posted Date
- 2019-10-22
- Lead Sponsor
- Syndax Pharmaceuticals
- Target Recruit Count
- 49
- Registration Number
- NCT00866333
- Locations
- 🇺🇸
Johns Hopkins, Baltimore, Maryland, United States
🇺🇸Tower Cancer Research Foundation, Beverly Hills, California, United States
🇺🇸Roswell Park Cancer Institute, Buffalo, New York, United States
Study of the Effect of the Addition of SNDX-275 (Entinostat) to Continued Aromatase Inhibitor (AI) Therapy in Postmenopausal Women With ER+ Breast Cancer Whose Disease is Progressing
- Conditions
- ER+ Breast Cancer
- Interventions
- Drug: EntinostatDrug: Aromatase Inhibitor (AI) Therapy
- First Posted Date
- 2009-01-26
- Last Posted Date
- 2022-06-30
- Lead Sponsor
- Syndax Pharmaceuticals
- Target Recruit Count
- 27
- Registration Number
- NCT00828854
- Locations
- 🇬🇧
University College London Hospitals, London, United Kingdom
🇬🇧Christie Hospital, Manchester Breast Centre, Manchester, United Kingdom
🇬🇧Velindre Hospital - Whitchurch, Cardiff, United Kingdom
A Phase I, Multicenter, Open Label Study on the Effects of SNDX-275 on Expression of Biomarkers in Subjects With Newly Diagnosed Breast Cancer
- Conditions
- Breast Cancer
- Interventions
- Drug: SNDX-275
- First Posted Date
- 2008-09-17
- Last Posted Date
- 2022-06-06
- Lead Sponsor
- Syndax Pharmaceuticals
- Target Recruit Count
- 1
- Registration Number
- NCT00754312
- Locations
- 🇺🇸
Monet Bowling, MD, Indianapolis, Indiana, United States
A Phase 2 Exploratory Study of Erlotinib and SNDX-275 in Participants With Non-small Cell Lung Carcinoma Who Are Progressing on Erlotinib
- First Posted Date
- 2008-09-10
- Last Posted Date
- 2023-07-06
- Lead Sponsor
- Syndax Pharmaceuticals
- Target Recruit Count
- 8
- Registration Number
- NCT00750698
- Locations
- 🇺🇸
Rush University Medical Center, Chicago, Illinois, United States
🇺🇸University of Miami, Miami, Florida, United States
🇺🇸Sharp Clinical Oncology Research, San Diego, California, United States
Study to Evaluate Exemestane With and Without Entinostat (SNDX-275) in Treatment of Postmenopausal Women With Advanced Breast Cancer
- Conditions
- ER+ Breast CancerBreast CancerEstrogen Receptor-Positive Breast CancerBreast Cancer, Estrogen Receptor-Positive
- Interventions
- First Posted Date
- 2008-05-13
- Last Posted Date
- 2022-05-11
- Lead Sponsor
- Syndax Pharmaceuticals
- Target Recruit Count
- 130
- Registration Number
- NCT00676663
- Locations
- 🇺🇸
Chattanooga Oncology Hematology Associates, Chattanooga, Tennessee, United States
🇺🇸Florida Cancer Specialists, Fort Myers, Florida, United States
🇺🇸Memorial Cancer Institute, Hollywood, Florida, United States
Study to Evaluate Erlotinib With or Without SNDX-275 (Entinostat) in the Treatment of Patients With Advanced NSCLC
- Conditions
- Carcinoma, Non-Small Cell LungNon-Small-Cell Lung Carcinoma
- Interventions
- First Posted Date
- 2008-01-28
- Last Posted Date
- 2022-08-22
- Lead Sponsor
- Syndax Pharmaceuticals
- Target Recruit Count
- 141
- Registration Number
- NCT00602030
- Locations
- 🇺🇸
Fairfax Northern Virginia Hematology-Oncology, Fairfax, Virginia, United States
🇺🇸HOPE (Hematology Oncology Physicians & Extenders), Tucson, Arizona, United States
🇺🇸Oncology Associates of Oregon, Eugene, Oregon, United States